Article Text

Download PDFPDF
Akkermansia muciniphila derived tripeptide jams the gear of sepsis, inflammation and mortality
  1. Patrice D Cani1,2,3,
  2. Matthias Van Hul1,2,
  3. Radu Bachmann4,5
  1. 1 Louvain Drug Research Institute (LDRI), Metabolism and Nutrition research group (MNUT), UCLouvain, Université catholique de Louvain, Brussels, Belgium
  2. 2 WELBIO Department, WEL Research Institute, Wavre, Belgium
  3. 3 Institute of Experimental and Clinical Research (IREC), UCLouvain, Université catholique de Louvain, Brussels, Belgium
  4. 4 Colorectal Surgery Unit, Cliniques universitaires Saint-Luc, UCLouvain, Brussels, Belgium
  5. 5 Cliniques des Pathologies Tumorales du Colon et de Rectum (CPTCR), Cliniques universitaires Saint-Luc Institut Roi Albert II, Bruxelles, Belgium
  1. Correspondence to Professor Patrice D Cani, Louvain Drug Research Institute (LDRI), Metabolism and Nutrition research group (MNUT), UCLouvain, Université catholique de Louvain, Brussels 1200, Belgium; patrice.cani{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Sepsis constitutes a global burden on medical care and accounts for nearly 20% of reported global mortality.1 The development of sepsis is complex, though the triggering of a disproportional systemic proinflammatory response is considered pivotal in driving organ dysfunction and subsequent mortality. As functional pattern recognition receptors, toll-like receptors (TLRs) play a predominant role in this context. Hence, approaches aimed at limiting their activation are considered valuable strategies for mitigating the organ damage and mortality occurring during the advancement of sepsis. The gut microbiota’s central importance in human health and its influence on sepsis progression, prompted a closer examination of specific bacterial strains.2 Akkermansia muciniphila (Akkermansia) holds particular potential as a next-generation beneficial bacteria in this context as we and others showed promising effects of this bacterium in preventing the progression of various pathological conditions linked to disruptions in immune system regulation and metabolic imbalances (ie, type 2 diabetes, obesity, hepatic steatosis, cancer therapies) (for review3). Akkermansia has the capability to stimulate appropriate immune responses and produces biologically active compounds that can influence the functioning of nearly every system in the body. We recently discovered that live Akkermansia protects against anastomotic leakage-induced peritonitis/sepsis and mortality by improving wound healing during colonic wall defect through mechanisms possibly involving interleukin (IL)-22 signalling and requiring TLR signalling through myeloid differentiation primary response 88 (MyD88) in the intestinal cells (figure 1).4 Among the suggested mechanisms, it was previously shown that Akkermansia produces several active compounds such as specific proteins (eg, Amuc_1100, P9), bioactive lipids (eg, diacyl phosphatidylethanolamine) or …

View Full Text


  • Contributors All authors contributed equally to the discussion, writing, correction and drawing of the figure.

  • Competing interests PDC is inventor on patent applications dealing with the use of specific bacteria and components in the treatment of different diseases. PDC was cofounder of The Akkermansia Company SA and Enterosys S.A.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles

  • Gut microbiota
    Shihao Xie Jiaxin Li Fengyuan Lyu Qingming Xiong Peng Gu Yuqi Chen Meiling Chen Jingna Bao Xianglong Zhang Rongjuan Wei Youpeng Deng Hongzheng Wang Zhenhua Zeng Zhongqing Chen Yongqiang Deng Zhuoshi Lian Jie Zhao Wei Gong Ye Chen Ke-Xuan Liu Yi Duan Yong Jiang Hong-Wei Zhou Peng Chen